Literature DB >> 21126621

Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure.

Navin K Kapur1, Kevin S Heffernan, Adil A Yunis, Peter Parpos, Michael S Kiernan, Nikhil A Sahasrabudhe, Carey D Kimmelstiel, David A Kass, Richard H Karas, Michael E Mendelsohn.   

Abstract

Progressive left ventricular (LV) dysfunction induces expression of the cytokine transforming growth factor-β1. Endoglin (CD105) is a transforming growth factor-β1 co-receptor that is released into the circulation as soluble endoglin (sEng). The objective of the present study was to assess the serum levels of sEng in patients with heart failure and to identify the predictive value of sEng for detecting elevated left ventricular end-diastolic pressures (LVEDPs). We measured the sEng levels in 82 consecutive patients with suspected LV dysfunction referred for determination of left heart filling pressures using cardiac catheterization. Among these subjects, the sEng levels correlated with the LVEDP (R = 0.689; p <0.0001), irrespective of the LV ejection fraction. Using a receiving operating characteristic curve, the sEng levels predicted an LVEDP of ≥16 mm Hg with an area under the curve of 0.85, exceeding the measured area under the curves for both atrial and brain natriuretic peptide, currently used biomarkers for heart failure diagnosis (atrial natriuretic peptide 0.68 and brain natriuretic peptide 0.65; p <0.01 vs sEng). In 10 subjects receiving medical therapy guided by invasive hemodynamic monitoring for heart failure, decreased a pulmonary capillary wedge pressure was associated with a reduced sEng level (R = 0.75, p = 0.008). Finally, compared to 25 healthy controls, the sEng levels were elevated in subjects with suspected LV dysfunction (3,589 ± 588 vs 4,257 ± 966 pg/ml, respectively, p <0.005) and correlated directly with the New York Heart Association class (R = 0.501, p<0.001). In conclusion, circulating levels of sEng are elevated in patients with increased LVEDP and New York Heart Association class, irrespective of the LV ejection fraction. sEng levels also decreased in association with a reduced cardiac filling pressure after diuresis. These findings have identified circulating sEng as a sensitive measure of elevated left heart filling pressures.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21126621      PMCID: PMC3353730          DOI: 10.1016/j.amjcard.2010.08.018

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  21 in total

1.  Soluble endoglin contributes to the pathogenesis of preeclampsia.

Authors:  Shivalingappa Venkatesha; Mourad Toporsian; Chun Lam; Jun-ichi Hanai; Tadanori Mammoto; Yeon M Kim; Yuval Bdolah; Kee-Hak Lim; Hai-Tao Yuan; Towia A Libermann; Isaac E Stillman; Drucilla Roberts; Patricia A D'Amore; Franklin H Epstein; Frank W Sellke; Roberto Romero; Vikas P Sukhatme; Michelle Letarte; S Ananth Karumanchi
Journal:  Nat Med       Date:  2006-06-04       Impact factor: 53.440

Review 2.  Death begets failure in the heart.

Authors:  Roger S-Y Foo; Kartik Mani; Richard N Kitsis
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

3.  Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis.

Authors:  Luisa Diez-Marques; Rocio Ortega-Velazquez; Carmen Langa; Alicia Rodriguez-Barbero; Jose Miguel Lopez-Novoa; Santiago Lamas; Carmelo Bernabeu
Journal:  Biochim Biophys Acta       Date:  2002-05-21

4.  Defective angiogenesis in mice lacking endoglin.

Authors:  D Y Li; L K Sorensen; B S Brooke; L D Urness; E C Davis; D G Taylor; B B Boak; D P Wendel
Journal:  Science       Date:  1999-05-28       Impact factor: 47.728

5.  Examining potential therapies targeting myocardial fibrosis through the inhibition of transforming growth factor-beta 1.

Authors:  Razi Khan
Journal:  Cardiology       Date:  2007-02-15       Impact factor: 1.869

6.  Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts.

Authors:  A Leask; D J Abraham; D R Finlay; A Holmes; D Pennington; X Shi-Wen; Y Chen; K Venstrom; X Dou; M Ponticos; C Black; C Bernabeu; J K Jackman; P R Findell; M K Connolly
Journal:  Arthritis Rheum       Date:  2002-07

7.  Endoglin (CD105) expression in the human heart throughout gestation: an immunohistochemical study.

Authors:  Barresi Valeria; Grosso Maddalena; Vitarelli Enrica; Triolo Onofrio; Barresi Gaetano
Journal:  Reprod Sci       Date:  2008-12       Impact factor: 3.060

8.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.

Authors:  Elisabeth M Zeisberg; Oleg Tarnavski; Michael Zeisberg; Adam L Dorfman; Julie R McMullen; Erika Gustafsson; Anil Chandraker; Xueli Yuan; William T Pu; Anita B Roberts; Eric G Neilson; Mohamed H Sayegh; Seigo Izumo; Raghu Kalluri
Journal:  Nat Med       Date:  2007-07-29       Impact factor: 53.440

9.  Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma.

Authors:  Eray Yagmur; Mohamed Rizk; Sven Stanzel; Claus Hellerbrand; Frank Lammert; Christian Trautwein; Hermann E Wasmuth; Axel M Gressner
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-09       Impact factor: 2.566

10.  The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure.

Authors:  A I Larsen; K Dickstein; N S Ahmadi; T Aarsland; J T Kvaløy; C Hall
Journal:  Eur J Heart Fail       Date:  2006-02-07       Impact factor: 15.534

View more
  19 in total

1.  Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.

Authors:  Navin K Kapur; Szuhuei Wilson; Adil A Yunis; Xiaoying Qiao; Emily Mackey; Vikram Paruchuri; Corey Baker; Mark J Aronovitz; S Ananth Karumanchi; Michelle Letarte; David A Kass; Michael E Mendelsohn; Richard H Karas
Journal:  Circulation       Date:  2012-05-16       Impact factor: 29.690

Review 2.  The Role of Endoglin in Myocardial Fibrosis.

Authors:  Kou-Gi Shyu
Journal:  Acta Cardiol Sin       Date:  2017-09       Impact factor: 2.672

3.  Endothelial function and soluble endoglin in smokers with heart failure.

Authors:  Kevin S Heffernan; Jeffrey T Kuvin; Ayan R Patel; Richard H Karas; Navin K Kapur
Journal:  Clin Cardiol       Date:  2011-11-28       Impact factor: 2.882

Review 4.  Novel biomarkers in acute heart failure.

Authors:  Marat Yanavitski; Michael M Givertz
Journal:  Curr Heart Fail Rep       Date:  2011-09

Review 5.  A Comprehensive Outlook on Dilated Cardiomyopathy (DCM): State-Of-The-Art Developments with Special Emphasis on OMICS-Based Approaches.

Authors:  Vivek Sarohi; Shriya Srivastava; Trayambak Basak
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-01

6.  Appropriate Dose of Dapagliflozin Improves Cardiac Outcomes by Normalizing Mitochondrial Fission and Reducing Cardiomyocyte Apoptosis After Acute Myocardial Infarction.

Authors:  Zhong-Guo Fan; Yang Xu; Xi Chen; Ming-Yue Ji; Gen-Shan Ma
Journal:  Drug Des Devel Ther       Date:  2022-06-28       Impact factor: 4.319

7.  Endoglin selectively modulates transient receptor potential channel expression in left and right heart failure.

Authors:  Kevin J Morine; Vikram Paruchuri; Xiaoying Qiao; Mark Aronovitz; Gordon S Huggins; David DeNofrio; Michael S Kiernan; Richard H Karas; Navin K Kapur
Journal:  Cardiovasc Pathol       Date:  2016-08-21       Impact factor: 2.185

Review 8.  Can biomarkers help to diagnose early heart failure with preserved ejection fraction?

Authors:  Jaroslav Meluzín; Josef Tomandl
Journal:  Dis Markers       Date:  2015-01-31       Impact factor: 3.434

9.  MicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart.

Authors:  Bao-Wei Wang; Gong-Jhe Wu; Wen-Ping Cheng; Kou-Gi Shyu
Journal:  PLoS One       Date:  2014-01-02       Impact factor: 3.240

Review 10.  Endoglin: a critical mediator of cardiovascular health.

Authors:  Navin K Kapur; Kevin J Morine; Michelle Letarte
Journal:  Vasc Health Risk Manag       Date:  2013-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.